Pharmacodynamics of LY2963016 Compared to LANTUS in Subjects With Type 1 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 01 Jan 2017
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Eli Lilly
- 19 Sep 2014 Primary endpoint (Pharmacodynamics: Duration of Action of LY2963016 and Lantus) has been met.
- 19 Sep 2014 Results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
- 31 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History